Structure via PubChem · Public domain (PubChem)
venetoclax
Sign in to saveAlso known as Venclexta, ABT-199, 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide, GDC-0199
Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).
In the Vinony graph
Vinony's link graph records 496 inbound references to venetoclax, and connects out to apoptotic process, chronic lymphocytic leukemia and human chromosome 17.
Vinony files it under 4-Chlorophenyl compounds, Acylsulfonamides and Antineoplastic drugs.
Vinony links it to 12 Wikipedia language editions.
Key facts
- Drug.image
- Venetoclax.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 275
- Drug.image2
- Venetoclax.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Venclexta, Venclyxto
- Drug.MedlinePlus
- a616028
- Drug.DailyMedID
- Venetoclax
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- XX52
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C45H50ClN7O7S
- Molecular weight
- 868.4 g/mol
- IUPAC name
- 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
- SMILES
- CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C
- InChIKey
- LQBVNQSMGBZMKD-UHFFFAOYSA-N
- XLogP
- 8.2
- Polar surface area
- 183 Ų
- H-bond donors
- 3
- H-bond acceptors
- 11
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2016
- Admin. routes
- oral
- Indications
- chronic lymphocytic leukemia, multiple myeloma, non-Hodgkins lymphoma, neoplasm
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 867.318096
Show 6 more facts
- medical condition treated
- chronic lymphocytic leukemia
- chemical formula
- C₄₅H₅₀ClN₇O₇S
- canonical SMILES
- CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C
- subject has role
- antineoplastic
- Commons category
- Venetoclax
- physically interacts with
- BCL2 apoptosis regulator
Sources (9)
via Wikidata · CC0
~14 min read
Encyclopedic overview
12 sectionsContents
- Medical uses
- CLL/SLL
- Other types of leukemia
- Acute myeloid leukemia
- Side effects
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- Society and culture
- Research
- References
{{Infobox drug | image = Venetoclax.svg | image_class = skin-invert-image | width = 275 | alt = | image2 = Venetoclax.png | image_class2 = bg-transparent | alt2 = | caption =
| pronounce = | tradename = Venclexta, Venclyxto | Drugs.com = | MedlinePlus = a616028 | DailyMedID = Venetoclax | pregnancy_AU = C | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATC_prefix = L01 | ATC_suffix = XX52 | ATC_supplemental =
Excerpted from Wikipedia’s “venetoclax” article, available under the CC BY-SA 4.0 licence.